Drug · Small Molecule

Lomustine

CI-DRUG-00000347Explore in graph →NCIt C617 CHEMBL514 CIViC Approved

Regulatory

Approvals (5)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory5 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CEENU (DIN 00360414) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 1, 2019	Dec 31, 1976	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CEENU (DIN 00360422) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1976	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CEENU (DIN 00360430) under ATC L01AD02 LOMUSTINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1976

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	17	7	28	86	5	CA, US	Aug 4, 1976	1994-07
Hodgkin Lymphoma	Approved	—	0	0	0	0	1	US	Aug 4, 1976	—
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	15	7	15	48	0	—	—	2001-04
Leukemia	Phase3	Phase 3	0	0	1	1	0	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Overexpression1
Bevacizumab + Lomustine

Clinical trials

Trials with this intervention (87)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 87 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07145112	Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma	recruiting	Phase 1	25	University of California, DavisOTHER	1	Sep 28, 2026	clinicaltrials
NCT05902169	Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD)

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: 7BRF0Z81KG
Aliases: 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, Ccnu, CCN-U, CCNU, Cecenu, Ceenu, CeeNU, Chloroethylcyclohexylnitrosourea, Chloroethylcyclo- Hexylnitrosourea, Citostal, Gleostine, GLEOSTINE, Lomeblastin, Lomustina, Lomustine, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, NSC-79037, Prava, RB-1509, WR-139017

Data updated 23 hours agoSource updated unknown

Identifiers

Codes (7)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01AD02	LOMUSTINE
DIN (Health Canada)	00360414	CEENU
DIN (Health Canada)